Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-28ζ CAR-T cells with shJNK
- Development stage
- Preclinical
- Lead developer
- University of Alabama at Birmingham
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intravenous
01
Overview
**HER2-28ζ CAR-T cells with shJNK** is an experimental, autologous human T-cell therapy engineered with a second-generation HER2-directed chimeric antigen receptor containing a CD28 costimulatory domain and CD3ζ signaling domain, together with a lentivirally encoded short-hairpin RNA that suppresses c-Jun N-terminal kinase 1 and 2 expression. The CAR directs T-cell recognition and killing of HER2-expressing tumor cells, while JNK knockdown modulates NFAT signaling, increases NFATc1-dependent granzyme B expression and degranulation, and enhanced antitumor cytotoxicity in preclinical ovarian cancer models. The construct was reported by researchers at the University of Alabama at Birmingham and remains a preclinical investigational cell-therapy approach for HER2-positive ovarian cancer.
- Other names
- HER2-28ζ CAR-T cells with shJNK
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-28ζ CAR-T cells with shJNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-28ζ CAR-T cells with shJNK.